Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · IEX Real-Time Price · USD
+0.91 (2.92%)
At close: Jun 21, 2024, 4:00 PM
-0.73 (-2.28%)
After-hours: Jun 21, 2024, 6:34 PM EDT

Company Description

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.

Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis.

In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases.

The company was incorporated in 2018 and is headquartered in Foster City, California.

Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals logo
Country United States
Founded 2018
IPO Date Jul 18, 2019
Industry Biotechnology
Sector Healthcare
Employees 264
CEO Christopher Peetz

Contact Details

989 East Hillsdale Boulevard, Suite 300
Foster City, California 94404
United States
Phone 650-667-4085
Website mirumpharma.com

Stock Details

Ticker Symbol MIRM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001759425
CUSIP Number 604749101
ISIN Number US6047491013
Employer ID 83-1281555
SIC Code 2834

Key Executives

Name Position
Christopher Peetz Chief Executive Officer and Director
Peter Radovich M.B.A., Ph.D. Chief Operating Officer and President
Dr. Pamela Vig Ph.D. Chief Scientific Officer and Head of Research
Lara Longpre MBA, MSC Chief Development Officer
Eric H. Bjerkholt M.B.A. Chief Financial Officer
Andrew McKibben Vice President of Investor Relations and Finance
Paul K. Ross Chief Compliance Officer
Erin Campany Senior Vice President of Human Resources
Dr. Ian Clements Ph.D. Consultant
Vinita P. Kumar Senior vice President of Quality

Latest SEC Filings

Date Type Title
Jun 17, 2024 8-K Current Report
Jun 6, 2024 8-K Current Report
May 31, 2024 8-K Current Report
May 8, 2024 10-Q Quarterly Report
May 8, 2024 8-K Current Report
Apr 23, 2024 ARS Filing
Apr 23, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 23, 2024 DEF 14A Other definitive proxy statements
Mar 15, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 15, 2024 10-K Annual Report